Innova Captab Share Price

Conference Call with Innova Captab Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 3 months 3 weeks ago

Pharmaceuticals company Innova Captab announced Q2FY26 results Revenue from Operations registered stellar growth of 19.5% to Rs 380.4 crore vs Rs 318.2 crore. Achieved EBITDA of Rs 56.1 crore vs Rs 51.9 crore in Q2 FY25. EBITDA margin for the quarter was 14.7%. PAT for the quarter stood at Rs 29.7 crore PAT margin was 7.8%. Vinay Lohariwala, Managing Director, Innova Captab, said: “Our strategic initiatives continue to deliver measurable outcomes, as evidenced by YoY revenue growth of 19.5% both in Q2 and H1FY26 reaching Rs 380 crore and Rs 732 crore respectively. We witnessed healthy volume growth, underscoring the sustained demand momentum and operational efficiency achieved through our scale-up efforts. During the quarter, our manufacturing capabilities were further strengthened with the successful inspection of our Cephalosporin plant in Baddi by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (UK-MHRA) and of our Jammu facility by the State Service of Ukraine on Medicines and Drugs Control (SMDC). These milestones underscore our adherence to global quality standards and reinforce our presence in key international markets. With multiple growth levers in motion — including substantial room for scale-up, geographic diversification, and a robust product pipeline — we are well-positioned to sustain our growth trajectory and deliver a resilient performance across both our business verticals.” Result PDF

• Trendlyne
• 6 months 1 week ago

Pharmaceuticals company Innova Captab announced Q1FY26 results Revenue from Operations recorded robust growth of 19% YoY, reaching Rs 351.5 crore in Q1FY26, driven by introduction of new products (including that from newly commissioned Jammu plant) and market expansion. Consolidated EBITDA stood at Rs 56.6 crore vs Rs 44.3 crore in Q1FY25 signifying solid YoY growth of 28%. EBITDA margins improved to 16.1% vs 15.1% in Q1FY25, mainly supported by expanded gross margin. PAT increased by 5% YoY to Rs 31.0 crore, reflecting resilience in the face of increased depreciation and finance expenses. PAT margin stood at 8.8%. Vinay Lohariwala, Managing Director, Innova Captab, said: “The first quarter has provided us with a strong and confident start to the financial year 2026. We delivered solid growth, reflected in both a healthy expansion of our topline and a notable improvement in operating profitability. We continued to make steady progress on our strategic initiatives, in line with our plans. Our newly commissioned facility in Jammu gained momentum during the quarter, and we expect this traction to accelerate in the coming quarters and beyond. In a pivotal move, we have reorganized our business areas into two focused verticals: CDMO and Branded Generics to synchronize with our strategic vision. Over the years, we’ve built robust partnerships with our CDMO clients across global markets, while simultaneously strengthening our direct presence in India and other key international geographies. We remain committed to executing our strategy with discipline and agility. With a strong foundation in place, we are confident in our ability to drive sustainable growth and longterm value for all stakeholders.” Result PDF

• Trendlyne
• 9 months 2 weeks ago